-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex Announces Amended License Agreement With University Of Pittsburgh For Gene Therapy Technologies In Diabetes; Forms Subsidiary Convergen Biotech For Diabetes Program Development

Benzinga·02/18/2025 13:17:48
Listen to the news

Signs an Amended & Restated License Agreement for Multiple Technologies for Gene Therapy for Type 1 and

Type 2 Diabetes

Forms a Wholly-Owned Subsidiary, Convergen Biotech, Inc., to Focus Diabetes Program Development

AUSTIN, Texas, Feb. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the advancement of its diabetes gene therapy program, including its relationship and collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt). The parties have updated and consolidated the Company's existing license agreements for technologies from Pitt into a new exclusive license agreement for multiple technologies relating to the development of a gene therapy product for both T1D and T2D. Additionally, the Company has formed a wholly-owned subsidiary, Convergen Biotech, Inc., which will focus on the Company's diabetes program development.